Company news

Agenus Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

August 19, 2025

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

August 11, 2025

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

July 31, 2025

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

July 25, 2025

Agenus’ BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

July 6, 2025

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

June 17, 2025

Agenus Announces Virtual Annual Shareholders Meeting

June 10, 2025

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US

June 3, 2025

Agenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer

May 30, 2025

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 15, 2025

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

May 12, 2025

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

April 29, 2025

Agenus’ BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

April 28, 2025

Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

April 25, 2025

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

April 23, 2025

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

March 25, 2025

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

March 19, 2025

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

March 11, 2025

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

February 26, 2025

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

February 25, 2025

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

February 25, 2025

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

February 24, 2025

CORRECTING and REPLACING Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

February 23, 2025

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

January 28, 2025

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

January 21, 2025

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

December 17, 2024

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

December 4, 2024

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

November 26, 2024

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

November 11, 2024

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

November 6, 2024

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

November 4, 2024

Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024

September 12, 2024

Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024

September 8, 2024

Agenus to Participate in September Investor Conferences

September 2, 2024

Agenus Reports Second Quarter 2024 Operational and Financial Results

August 7, 2024

Agenus Announces Appointment of Tom Harrison to Board of Directors

August 7, 2024

Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers

August 6, 2024

Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update

July 25, 2024

Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer

July 17, 2024

Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference

June 27, 2024

Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies

June 26, 2024

Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors

June 16, 2024

Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50

June 12, 2024

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 23, 2024

Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting

May 22, 2024

FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer

May 15, 2024

Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement

May 6, 2024

Agenus Reports First Quarter 2024 Results

May 6, 2024

Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement

April 30, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 26 decks. Every deck is listed under its year.